SynthesisRadiation oncology (London, England)2026
Spatially fractionated radiation therapy for bulky tumors: a systematic review of clinical outcomes and dosimetric challenges.
Synthesis in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lattice SFRT in a geriatric patient with an initially inoperable leg bulky sarcoma: case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional radiotherapy for bulky tumors is often limited by normal tissue tolerance, restricting dose escalation and increasing toxicity. Spatially Fractionated Radiation Therapy (SFRT), including GRID and Lattice Radiotherapy (LRT), delivers intentionally heterogeneous dose distributions to overcome these limitations. This systematic review summarizes the clinical application, outcomes, and dosimetric variability of SFRT in the treatment of bulky tumors. A systematic literature search of the MEDLINE database was performed for studies published between January 2010 and June 2025. Eligible English-language studies reporting original clinical data on SFRT, including case reports, case series, retrospective analyses, and prospective trials, were included. Data on patient and tumor characteristics, treatment intent, SFRT technique, clinical response, and toxicity were extracted, and methodological quality was assessed using the ROBINS-I framework. Twenty-nine studies involving 513 patients and 553 lesions were included. The most commonly treated sites were the thorax (28.8%), pelvis (24.7%) and abdomen (23.3%), with sarcomas (48.0%) carcinomas (14.5%) and non-small cell lung cancer (10.4%) being the predominant histologies. SFRT was mainly delivered with palliative intent (216 cases). Tumor shrinkage was reported in approximately 80% of lesions, with consistent symptom relief. Treatment-related toxicity was generally mild, with most adverse events graded as 1-2; severe toxicities (Grade ≥ 3) were rare. Despite favorable clinical outcomes and an acceptable safety profile, substantial heterogeneity in dosimetric parameters, including valley-to-peak dose ratio and fractionation schemes, was observed across studies. SFRT appears to be a feasible and effective option for bulky tumors, particularly in the palliative setting. However, the lack of dosimetric standardization and prospective data highlights the need for harmonized protocols and well-designed clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.